Sorry, you need to enable JavaScript to visit this website.
  1. Home
  2. Our Science
  3. Clinical Trials
  4. Plain Language Study Results Summaries

Plain Language Study Results Summaries

What Are Plain Language Study Results Summaries?

Plain Language Study Results Summaries are descriptions in everyday language of the design and results of clinical studies. These summaries, also called plain language summaries, simple summaries, and trial results summaries, are intended to make clinical results understandable and accessible to patients, healthcare providers, caregivers, researchers, and a general audience.

Please use the search function below to find Plain Language Study Results Summaries for Pfizer-sponsored global clinical trials.

Filter Results

Refine your search results by using the dropdown filters below. Click “reset” to return to the full list of available studies.

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
Category & Conditions: Cancer
Study Phase : 3
Medicine: XALKORI®(CRIZOTINIB)
Language: English
ViewDownloadPrint
Efficacy and Safety of Tofacitinib in Psoriatic Arthritis: Comparator Study
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: English
ViewDownloadPrint
Efficacy and safety of tofacitinib in young patients aged 2 to less than 18 years with polyarticular course Juvenile Idiopathic Arthritis (JIA)
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: English
ViewDownloadPrint
Effectiveness and Safety of Tofacitinib in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA) That Affects the Whole Body
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: English
ViewDownloadPrint
Wirksamkeit und Sicherheit von Tofacitinib bei Kindern und Jugendlichen mit systemischer juveniler idiopathischer Arthritis (sJIA) mit Beteiligung des gesamten Körpers
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: German
ViewDownloadPrint
A tofacitinib hatásossága és biztonságossága a teljes testet érintő szisztémás juvenilis idiopátiás artritisz (sJIA) kezelésében gyermekek és serdülők körében
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: Hungarian
ViewDownloadPrint
Efficacia e sicurezza di tofacitinib in bambini e adolescenti affetti da artrite idiopatica giovanile sistemica (AIGS) che interessa l’intero organismo
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: Italian
ViewDownloadPrint
Skuteczność i bezpieczeństwo stosowania tofacytynibu u dzieci i młodzieży z układową postacią młodzieńczego idiopatycznego zapalenia stawów (uMIZS), które wpływa na cały organizm
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: Polish
ViewDownloadPrint
Eficacia y seguridad de tofacitinib en niños y adolescentes con artritis idiopática juvenil sistémica (AIJs) que afecta a todo el organismo
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: Spanish
ViewDownloadPrint
: Efficacy and Safety of Tofacitinib in Patients With Active Ankylosing Spondylitis (AS)
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 3
Medicine: XELJANZ®(TOFACITINIB)
Language: English
ViewDownloadPrint
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 4
Medicine: XELJANZ®(TOFACITINIB)
Language: English
ViewDownloadPrint
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Category & Conditions: Immune System Diseases and Conditions
Study Phase : 4
Medicine: XELJANZ®(TOFACITINIB)
Language: English
ViewDownloadPrint